Report Details:
15 Companies Covered
150 Pages
The Global Genetic Testing Market to Reach USD 88.64 Billion by 2035 at a CAGR of 18.82% through the Forecast Period
Market Overview
The global genetic testing market is experiencing rapid expansion, driven by rising awareness of hereditary diseases, increased demand for personalized medicine, and the growing importance of early disease detection.
The genetic testing market was valued at USD 13.3 billion in 2024 and is projected to reach USD 15.8 billion in 2025. The market is expected to continue its strong growth trajectory, reaching USD 88.64 billion by 2035, reflecting an impressive compound annual growth rate (CAGR) of 18.82% during the forecast period (2025–2035).
The increased adoption of genetic testing across oncology, prenatal screening, ancestry research, and pharmacogenomics is shaping market evolution. Rising consumer inclination toward preventive healthcare has accelerated the demand for at-home test kits and direct-to-consumer genetic testing solutions.
Market growth is also influenced by advancements in next-generation sequencing (NGS), declining test costs, wider availability of test panels, and improvements in healthcare infrastructure in emerging markets.
The expansion of reimbursement policies for certain hereditary cancer tests is further supporting the adoption of clinical genetic testing in hospitals and diagnostic laboratories. The market’s future is aligned with technological innovations that enable fast, accurate, and large-scale sequencing.
Segment Insights
The genetic testing market is segmented based on type, application, technology, and end user. The diagnostic testing segment leads the market due to increasing demand for identifying inherited genetic mutations that contribute to cancer and rare diseases.
Predictive and presymptomatic testing is another fast-growing segment, driven by rising consumer awareness about early-stage identification of health risks associated with conditions such as breast cancer, colon cancer, and neurodegenerative disorders.
In terms of technology, next-generation sequencing (NGS) is witnessing accelerated adoption due to its ability to analyze multiple genes simultaneously, making it the preferred method for creating comprehensive genetic profiles.
On the application front, oncology dominates the market. The increasing prevalence of hereditary cancer and wider availability of cancer-risk assessment tests have strengthened this segment’s growth.
The end-user landscape includes hospitals, diagnostic laboratories, and direct-to-consumer testing companies, with hospitals and clinical laboratories holding a dominant share owing to their superior diagnostic infrastructure and clinical reliability.
Regional Insights
North America held the largest share of the global genetic testing market, accounting for 45% of total revenue. Strong healthcare infrastructure, early adoption of advanced technologies, and the presence of major market players contribute significantly to the region’s dominance.
High consumer awareness and increasing use of genetic testing for cancer screening and personalized medicine further accelerate market expansion.
Europe represented the second-largest regional market, holding nearly 30% of the market share. The region’s growth is supported by favorable regulatory policies, strong investments in genomic research, and widespread adoption of genetic testing across public healthcare systems.
Countries such as Germany, France, and the United Kingdom are at the forefront of implementing precision medicine initiatives.
Asia-Pacific held around 20% of the global share and is expected to grow rapidly due to rising disposable income, improving healthcare access, and higher adoption of genetic testing for chronic disease diagnosis. Increasing government focus on biotechnology research and the expansion of private diagnostic networks are fueling market demand.
The Middle East and Africa region held 5% of the market share. Growing awareness of early disease detection and expanding healthcare investments are gradually increasing the adoption of genetic testing services.
Key Players
Key companies operating in the global genetic testing market include Myriad Genetics, Thermo Fisher Scientific, Illumina, Fulgent Genetics, and other regional and global competitors.
These players are focusing on innovation, strategic partnerships, and technology development to strengthen their market presence and expand testing capabilities.
Industry Developments
- In August 2025, Illumina partnered with a leading healthcare organization to expand access to genomic sequencing services.
- In September 2025, Myriad Genetics launched a new hereditary cancer test to enhance early detection and improve treatment planning.
- In October 2025, Thermo Fisher Scientific unveiled a digital platform designed to streamline genetic test processing for clinical laboratories.
Key Findings
- The global genetic testing market is projected to grow from USD 15.8 billion in 2025 to USD 88.64 billion by 2035 at an 18.82% CAGR, driven by increased adoption of preventive healthcare and personalized medicine.
- North America led the market with a 45% share due to strong technological adoption and access to advanced diagnostic infrastructure, while Asia-Pacific emerged as the fastest-growing region.
- Oncology remained the dominant application segment as genetic testing for hereditary cancer risk continues to increase among both clinicians and consumers.
- Market expansion was reinforced by continuous innovation, with companies launching new genetic screening solutions and digital platforms to improve accessibility and testing efficiency.